Skip to main content
. Author manuscript; available in PMC: 2021 Oct 7.
Published in final edited form as: J Thorac Oncol. 2020 Aug 28;15(12):1871–1879. doi: 10.1016/j.jtho.2020.08.017

Table 2.

Gene-level germline rare, deleterious variant (RDV) burden on ATM in all study cohorts.

Discovery cohort Validation cohort Combined cohort
Case
(513)
Control
(3423)
Case
(472)
Control
(3417)
Case
(989)
Control
(6981)
ATM Gene
# Variants 4 7 6 8 9 14
# Unique individuals 5
(0.97%)
8
(0.23%)
7
(1.48%)
9
(0.26%)
12
(1.21%)
17
(0.24%)
OR (p-val)
[95% CI]
4.05 (0.02)
[1.3–11.9]
5.50 (1.37e-03)
[2.0–14.4]
4.58 (1.66e-04)
[2.2–9.5]